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A B S T R A C T
Background and objectives: Central nervous system (CNS) malignancy is the commonest cause of cancer death in
children and adolescents (0–19 years) in high-income settings. There is limited data on survival inequalities by
race/ethnicity and socioeconomic position (SEP), for young patients, we aim to analyse their influence on
survival from childhood CNS tumour.
Methods: 9577 children and adolescents diagnosed with primary malignant CNS tumours during 2000–2015,
followed up until Dec 31 st, 2015, and reported to cancer registries (Surveillance, Epidemiology and End Results
programme) were included in the analysis. Cox regression models estimated the hazard ratios for race/ethnicity,
SEP, and individual insurance status, adjusting for sex, age, diagnostic period, and tumour type. Individual-level
insurance status data were available from 2007.
Results: 62.5 % children and adolescents were non-Hispanic White, 10.6 % were non-Hispanic Black and 26.9 %
were Hispanic. Race/ethnicity was strongly associated with survival (p < 0.001), even after adjusting for SEP,
with Black (HR=1.39 [95 %CI 1.23–1.58]) and Hispanic children (HR=1.40 [95 %CI 1.28–1.54]) having
higher hazards of death than White children. This association remained after adjusting for insurance status.
There was an apparent positive association between SEP and survival that was largely attenuated after adjust-
ment for insurance status (p= 0.20). Survival was comparable between those privately and Medicaid-insured.
Conclusions: Non-Hispanic Black and Hispanic children had lower survival than their White counterparts. This
association, not fully explained by differences in SEP, tumour subtype or health insurance, could be related to
racially/ethnically-driven barriers to optimal healthcare, warranting further investigation.
1. Introduction
Cancer is one of the most common causes of childhood mortality in
high-income settings. In the United States (US) in 2017, an estimated
15270 new cases of cancer occurred in children (0–14 years) and
adolescents (15–19 years), with 1790 deaths in these age groups [1].
Central nervous system (CNS) tumours are the second most common
group of cancers diagnosed in children after leukemia, yet they re-
present the first cause of death from childhood cancer in the US [2].
Whilst the US has seen impressive gains in cancer survival for
children and adolescents over the last few decades, the improvement
has not been equal across the population [3,4]. Disparities in survival
between Black and White children diagnosed with leukemia were first
reported in the literature in the 1970s [5]. Over the last 50 years,
disparities have recurrently been described across racial/ethnic groups
for a range of childhood and adolescent cancers, most notably for acute
lymphoblastic leukemia (ALL) [3,5–8]. Previous studies yielded con-
flicting results on the relation between socioeconomic position (SEP)
and survival from childhood and adolescent cancer [9]; a more recent
literature review of the relation between parental SEP and survival for
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childhood cancer in high income settings, including the US and several
European countries, reported heterogeneous methods and results, and
discussed the potential underlying mechanisms [10]. For childhood
CNS tumour more specifically, data on the influence of race/ethnicity
on survival are also conflicting, with several US studies reporting lower
survival in non-White racial/ethnic groups [8,11–13], but one study
reporting no disparities [14]. Using a mediation analysis, Kehm and
colleagues found that the racial disparities in CNS tumour survival
between 2000 and 2011 were not mediated by SEP [13]. The most
recent of these studies, based on data covering years 2001–2008 re-
ported a higher hazard of death for non-Hispanic black patients than
non-Hispanic white ones (HR=1.24 [95 % Confidence Interval
1.10–1.40]) but the association was not as clear for Hispanic patients
(HR 1.14 [0.94–1.38]) [12].
With regards to SEP, survival disparities by SEP have been reported
in adults diagnosed with CNS tumour in a high income setting [15–17],
but data are sparse for children. One study reported poorer survival in
lower socio-economic groups in Texas [11]. Studies in South Korea and
Switzerland showed an adverse effect of low SEP on survival [18,19],
however a British study did not show an effect of SEP on survival from
CNS tumour in children [20].
Using recent cancer registry data from the SEER (Surveillance,
Epidemiology, and End Results) programme covering years 2000–2015,
this study examines survival disparities by race/ethnicity and SEP, in a
large US population-based cohort of children and adolescents with CNS
tumour.
2. Materials and methods
2.1. Study design
This is a population-based cohort study comprised of routinely-
collected cancer registry data from the SEER Programme of the
National Cancer Institute (Nov 2017 data release). Since 2000, SEER
has included 18 registries (“SEER 18”) covering an estimated 34.6 % of
the US population. All children and adolescents aged 0–19 years at
diagnosis (hereafter referred to as ‘children’) with a first primary ma-
lignant CNS tumour diagnosed between Jan 1, 2000 and Dec 31, 2015
and residing in the areas covered by SEER 18, were included.
Information about the vital status was collected by SEER registries
from routine linkage to the national death index database. Follow-up
time for overall survival was computed as the number of days between
the date of diagnosis and the earliest of: date of death from any cause,
date of last contact (if censored alive), or end date of the study period
(Dec 31, 2015). Death was considered irrespective of the cause, as there
are few competing causes of death in this age group in high-income
countries.
2.2. Information on race/ethnicity and SEP
Race was recorded by the SEER registries from self-reported/guar-
dian identification, documentation in the medical records, or death
certificates [21]. Hispanic ethnicity was derived by SEER from an al-
gorithm based on the North American Association of Central Cancer
Registries (NAACCR) Hispanic Identification Algorithm [22]. We con-
sidered three groups of race/ethnicity: non-Hispanic White (referred to
as ‘White’), non-Hispanic Black (referred to as ‘Black’), and Hispanic.
Other races/ethnicities were not included due to small numbers.
The SEP measure was based on the area of residence at diagnosis, at
the census tract level (typical population size 4000–8000). The Yost
Index is constructed by SEER using a factor analysis of seven socio-
economic variables [23,24] including: median household income,
median house value, median rent, percent below 150 % of poverty line,
education index, percent working class, and percent unemployed. The
composite score was grouped into quintiles of the national distribution,
with the 1st quintile being people living in the most deprived areas, and
the 5th quintile those in the least deprived areas. From 2007 onwards,
individual-level data on health insurance status were also available;
classified by SEER as privately insured, insured through Medicaid
(state-funded), unspecified insurance, uninsured, or unknown.
Data were retrieved from a case listing session of SEER 18
(November 2017 submission), using SEER*Stat software version 8.3.5.
A total of 10755 malignant CNS tumours were recorded in 10,648
children during 2000–2015 (see Fig. 1). When a patient had several
records of a CNS tumour, we kept the earliest one (excluding 107 re-
cords). We excluded those with missing data on SEP (n= 178), on
race/ethnicity (n= 125), or with a category of ‘other race’ (n= 735),
and those whose survival time could not be calculated due to missing
date of diagnosis or those reported dead with missing date of death
(n= 33). A total of 9577 children with a CNS primary tumour were
included in the analyses (89.9 % of the eligible cohort).
Histological information was recorded and available for all tumours,
and six groups of childhood brain tumour were created based on
prognostic groupings described previously [14,25]. Information on
stage at diagnosis (Summary stage 2000) was available for 93.5 % of
the cohort, and classified as localised, regional or distant.
2.3. Statistical methods
We tested the proportional hazards assumption graphically with
plots of the log-cumulative hazard and Schoenfeld residual plots, and
with formal proportional hazard test (p= 0.07 for the race/ethnicity
and SEP). Overall survival probabilities at 1 and 5 years after diagnosis
were calculated using the Kaplan-Meier method. In order to measure
the effect of race/ethnicity and SEP on survival, hazard ratios (HR) and
their 95 % confidence intervals (CI) were computed from multivariable
Cox proportional hazards models, with all models being adjusted for
sex, age, year of diagnosis and tumour category. Additionally, we
constructed two sets of models, first analysing race/ethnicity and SEP
separately and then together, to assess their potential confounding ef-
fect on each other’s relation to the hazard of death. We also assessed
whether there was an interaction between race/ethnicity and SEP, by
adding an interaction term in the final model. Finally, with data on
insurance status available from 2007 onwards, a further model was
built restricted to patients diagnosed from 2007 (5429 participants).
Sensitivity analyses were performed by additionally adjusting the final
models for stage at diagnosis (excluding 624 children with missing
stage information), and by adding an interaction term between time
and race/ethnicity and SEP.
Data were analysed using Stata version 15 (College Station, Texas,
USA).
Fig. 1. Flow chart of exclusions from study.
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3. Results
Of the 9577 included children diagnosed with a first primary CNS
tumour during 2000–2015, 62.5 % (n=5982) were White, 10.6 %
(n=1015) were Black, and 26.9 % (n= 2580) were Hispanic
(Table 1a). Over 3 in 4 participants were aged 1–14 years at diagnosis,
with fewer girls than boys (46.4 % vs 53.6 %). Adolescents represented
18.1 % (n=1737) of the study participants. 30.5 % (n=2922) of
children had been diagnosed with a low-grade astrocytoma. 7.3 %
(n=436) of White children had high-grade astrocytoma, the propor-
tion was higher in Black and Hispanic children at 9.3 % (n=94) and
8.4 % (n=216), respectively. The vast majority of children (76.6 %)
had localised disease at diagnosis.
The distribution of SEP varied markedly between groups of race/
ethnicity, with more Black and Hispanic children living in the most
deprived areas (Chi squared test p < 0.001, see Fig. 2). Information on
individual-level insurance was available for 97.4 % of the 5429 children
diagnosed from 2007 onwards. 20.9 % (n=698) of White children had
Medicaid insurance while the proportion was 41.8 % (n= 251) for
Black and 53.5 % (n=799) for Hispanic children (p < 0.001, also see
Table 1b).
The 9577 children in the cohort contributed to 55052 person-years
of follow-up, with a median follow-up time of 56 months (IQR 15–117
months). Overall 1-year survival was 86.8 % (95 %CI 86.1–87.5 %) and
5-year survival was 74.5 % (95 %CI 73.6–75.5 %) (Table 2). Survival
was consistently lower for Black and Hispanic children, than for White
children (Fig. 3). One-year survival was 88.8 % (95 %CI 87.9–89.6 %)
for White, 84.5 % (82.1–86.7 %) for Black, and 83.1 % (81.5–84.5 %)
for Hispanic children, and 5-year survival was 78.1 % (76.9–79.2 %),
68.6 % (65.4–71.6 %) and 68.3 % (66.3–70.2 %), for White children,
Black and Hispanic children respectively. Children living in the most
deprived areas had lower survival than those in the least deprived SEP
areas, with 5-year survival of 70.7 % (68.4–72.9 %) and 78.8 %
(76.9–80.7 %) respectively (Table 2, Fig. 4). Differences in survival
were also observed by insurance status (2007–2015) with 5-year sur-
vival for privately insured children reaching 76.1 % (74.2–77.8 %)
compared to 70.3 % (67.7–72.8 %) in children insured on Medicaid
(Table 2). Survival was lowest for children diagnosed with high-grade
astrocytoma, with 5-year survival of 23.4 % (20.0–26.9 %). Survival in
children with distant disease was 56.6 % (95 %CI 51.8–60.7 %) com-
pared to 78.0 % (95 %CI 77.0–79.0 %) in those with localised disease.
The crude hazard ratio of death in Black compared to White chil-
dren was 1.54 (95 %CI 1.36–1.74) (Table 2). When adjusted for age,
sex, diagnostic period and tumour type, it was 1.46 (1.29–1.65), and
when additionally adjusted for SEP, the hazard ratio for Black children
remained stable (1.39 [1.23–1.58]) (Table 3). In the univariable ana-
lysis, Hispanic children had increased hazard of death compared to
White children (1.50 [1.37–1.65]) (Table 2). When adjusted for age,
sex, diagnostic period, and tumour type, the hazard ratio was stable,
and it decreased very slightly to 1.40 (95 %CI 1.28–1.54) on additional
adjustment for SEP (Table 3). The hazard of death was greatest in the
most deprived SEP regions, with evidence of a linear trend with in-
creasing degree of deprivation (p < 0.002 for test for trend, p= 0.6
for test of departures from linearity). After adjustment for age, sex,
Table 1a
Baseline characteristics of children and adolescents (0–19 years) diagnosed with first primary central nervous system tumour 2000–2015 by race/ethnicity
(n=9577).
Non-Hispanic white Non-Hispanic Black Hispanic Total
n (%) n (%) n (%) n (%)
Total 5982 62.5 1015 10.6 2580 26.9 9577 100.0
Age at diagnosis (years) < 1 287 4.8 60 5.9 178 6.9 525 5.5
1-4 1574 26.3 264 26 777 30.1 2,615 27.3
5-9 1574 26.3 280 27.6 762 29.5 2,616 27.3
10-14 1368 22.9 235 23.2 481 18.6 2,084 21.8
15-19 1179 19.7 176 17.3 382 14.8 1737 18.1
Sex Male 3248 54.3 500 49.3 1,381 53.5 5,129 53.6
Female 2734 45.7 515 50.7 1,199 46.5 4,448 46.4
Year of diagnosis 2000-2003 1594 26.6 252 24.8 607 23.5 2,453 25.6
2004-2007 1428 23.9 209 20.6 650 25.2 2,287 23.9
2008-2011 1535 25.7 275 27.1 663 25.7 2,473 25.8
2012-2015 1425 23.8 279 27.5 660 25.6 2,364 24.7
SEP (Yost) quintile 5 least deprived 1761 29.4 80 7.9 245 9.5 2,086 21.8
4 1437 24 157 15.5 382 14.8 1,976 20.6
3 1181 19.7 192 18.9 493 19.1 1,866 19.5
2 941 15.7 220 21.7 636 24.7 1,797 18.8
1 most deprived 662 11.1 366 36.1 824 31.9 1,852 19.3
Tumour type Astrocytoma (low grade) 1918 32.1 286 28.2 718 27.8 2922 30.5
Astrocytoma (high grade) 436 7.3 94 9.3 216 8.4 746 7.8
Astrocytoma (other) 449 7.5 82 8.1 182 7.1 713 7.4
Ependymoma 410 6.9 84 8.3 264 10.2 758 7.9
Medulloblastoma/PNET 1020 17.1 141 13.9 510 19.8 1,671 17.4
Other 1749 29.2 328 32.3 690 26.7 2,767 28.9
Stage Localised 4655 77.8 771 76.0 1,911 74.1 7,337 76.6
Regional 613 10.3 113 11.1 348 13.5 1,074 11.2
Distant 325 5.4 50 4.9 167 6.5 542 5.7
Unknown 389 6.5 81 8.0 154 5.9 624 6.5
Type of health insurance (2007 onwards) Total 3336 61.5 600 11.1 1,493 27.5 5429 100.0
Insured (private) 2111 63.3 256 42.7 534 35.8 2,901 53.4
Insured (Medicaid) 698 20.9 251 41.8 799 53.5 1,748 32.2
Insured (unknown type) 389 11.7 54 9 101 6.8 544 10
No insurance 42 1.3 19 3.2 33 2.2 94 1.7
Unknown 96 2.9 20 3.3 26 1.7 142 2.6
Astrocytoma high-grade (International Classification of Disease for Oncology 3rd Edition morphology codes 9401, 9411, 9440, 9441), astrocytoma low-grade (9421,
9424, 9410, 9420), astrocytoma other (9400, 9422, 9423, 9430), ependymoma (9391, 9392, 9393, 9394), and medulloblastoma/Primitive Neuro Ectodermal
Tumours (PNET) (9470, 9471, 9472, 9364, 9473). All remaining tumours were classified as ‘other’.
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diagnostic period, and tumour type, the hazard of death was 1.46
(1.29–1.66) times higher in children living in the most deprived versus
those in the least deprived SEP regions (Table 3). When additionally
adjusted for race/ethnicity however, the hazard ratio decreased to 1.23
(95 %CI 1.08–1.41).
When restricting to the 5429 children diagnosed from 2007 on-
wards, the hazard of death in the Medicaid-insured group was 1.18 (95
%CI 1.04–1.34) times higher compared to those privately insured (ad-
justed for age, sex, diagnostic period and tumour type) (Table 4). When
additionally adjusted for area-level SEP and race/ethnicity, insurance
status was no longer significantly associated with the risk of death
(HR=1.01 (95 %CI 0.87–1.16)). Overall, SEP was not associated with
the hazard of death when the analyses were additionally adjusted for
insurance status (p= 0.20), despite raised HRs in the most deprived
groups. The association with race/ethnicity remained strongly sig-
nificant when accounting for insurance status.
Sensitivity analyses additionally adjusted for stage at diagnosis
(excluding 624 participants) showed similar results (not shown).
Fig. 2. Distribution of SEP quintiles (1= most deprived, 5= least deprived) by race/ethnicity among children and adolescents diagnosed with CNS tumour during
2000–2015 in the US (p < 0.001).
Table 1b
Baseline characteristics of children and adolescents (0–19) diagnosed with first primary CNS tumour 2000–2015 by SEP (n= 9577).
1 (most deprived) 2 3 4 5 (least deprived) Total
n (%) n (%) n (%) n (%) n (%) n (%)
Total 1852 19.3 1797 18.8 1866 19.5 1976 20.6 2086 21.8 9577 100
Age at diagnosis (years) < 1 123 6.6 107 6.0 112 6.0 101 5.1 82 3.9 525 5.5
1-4 543 29.3 506 28.2 513 27.5 532 26.9 521 25 2615 27.3
5-9 535 28.9 502 27.9 476 25.5 546 27.6 557 26.7 2616 27.3
10-14 362 19.5 366 20.4 420 22.5 438 22.2 498 23.9 2084 21.8
15-19 289 15.6 316 17.6 345 18.5 359 18.2 428 20.5 1737 18.1
Sex Male 962 51.9 926 51.5 1025 54.9 1066 53.9 1150 55.1 5129 53.6
Female 890 48.1 871 48.5 841 45.1 910 46.1 936 44.9 4448 46.4
Year of diagnosis 2000-2003 451 24.4 488 27.2 459 24.6 503 25.5 552 26.5 2453 25.6
2004-2007 452 24.4 403 22.4 455 24.4 464 23.5 513 24.6 2287 23.9
2008-2011 477 25.8 450 25.0 478 25.6 538 27.2 530 25.4 2473 25.8
2012-2015 472 25.5 456 25.4 474 25.4 471 23.8 491 23.5 2364 24.7
Race/Ethnicity NH White 662 35.7 941 52.4 1181 63.3 1437 72.7 1761 84.4 5982 62.5
NH Black 366 19.8 220 12.2 192 10.3 157 7.9 80 3.8 1015 10.6
Hispanic 824 44.5 636 35.4 493 26.4 382 19.3 245 11.7 2580 26.9
Tumour type Astrocytoma (low grade) 539 29.1 536 29.8 578 31.0 601 30.4 668 32 2922 30.5
Astrocytoma (high grade) 149 8.0 157 8.7 137 7.3 142 7.2 161 7.7 746 7.8
Astrocytoma (other) 121 6.5 147 8.2 127 6.8 158 8 160 7.7 713 7.4
Ependymoma 168 9.1 156 8.7 141 7.6 147 7.4 146 7 758 7.9
Medulloblastoma/PNET 336 18.1 311 17.3 330 17.7 332 16.8 362 17.4 1671 17.4
Other 539 29.1 490 27.3 553 29.6 596 30.2 589 28.2 2767 28.9
Stage Localised 1390 75.0 1383 76.9 1429 76.6 1494 75.6 1,641 78.7 7337 76.6
Regional 237 12.8 203 11.3 206 11.0 222 11.2 206 9.9 1074 11.2
Distant 112 6.1 91 5.1 115 6.2 127 6.4 97 4.7 542 5.7
Unknown 113 6.1 120 6.7 116 6.2 133 6.8 142 6.8 624 6.5
Type of health insurance (2007 onwards) Total 1052 19.4 1022 18.8 1077 19.8 1124 20.7 1154 21 5429 100
Insured (private) 295 15.9 437 24.3 578 31.0 723 36.6 868 41.6 2901 30.3
Insured (Medicaid) 621 33.5 448 24.9 355 19.0 231 11.7 93 4.5 1748 18.3
Insured (unknown type) 83 4.5 84 4.7 95 5.1 135 6.8 147 7 544 5.7
No insurance 28 1.5 18 1.0 22 1.2 15 0.8 11 0.5 94 1
Unknown 25 1.3 35 1.9 27 1.4 20 1 35 1.7 142 1.5
Astrocytoma high-grade (International Classification of Disease for Oncology 3rd Edition morphology codes 9401, 9411, 9440, 9441), astrocytoma low-grade (9421,
9424, 9410, 9420), astrocytoma other (9400, 9422, 9423, 9430), ependymoma (9391, 9392, 9393, 9394), and medulloblastoma/Primitive Neuro Ectodermal
Tumours (PNET) (9470, 9471, 9472, 9364, 9473). All remaining tumours were classified as ‘other’.
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Table 2
1- and 5-year overall survival and univariable (crude) hazard ratios for death among children and adolescents (0–19 years) diagnosed with a first primary CNS
tumour between 2000–2015 (n= 9577).
Survival probabilities Univariate hazard ratio for death
1-year survival (95 % CI) 5-year survival (95 % CI) HR (95 % CI) p-valuea
All 86.8 (86.1–87.5) 74.5 (73.6–75.5)
Race/ethnicity NH White 88.8 (87.9–89.6) 78.1 (76.9–79.2) 1 (ref) < 0.0001
NH Black 84.5 (82.1–86.7) 68.6 (65.4–71.6) 1.54 (1.36–1.74)
Hispanic 83.1 (81.5–84.5) 68.3 (66.3–70.2) 1.50 (1.37–1.65)
SEP (Yost) quintile 5 least deprived 84.1 (82.3–85.8) 70.7 (68.4–72.9) 1 (ref) < 0.0001
4 87.5 (86.0–89.0) 75.8 (73.7–77.8) 1.17 (1.02–1.33)
3 86.6 (85.0–88.1) 74.0 (71.8–76.1) 1.29 (1.13–1.47)
2 85.0 (83.2–86.6) 72.5 (70.2–74.7) 1.38 (1.21–1.57)
1 most deprived 84.1 (82.3–85.8) 70.7 (68.4–72.9) 1.49 (1.31–1.70)
Age at diagnosis (years) < 1 70.6 (66.4–74.4) 59.7 (55.1–64.0) 1.87 (1.60–2.19) < 0.0001
1-4 85.8 (84.4–87.1) 74.4 (72.6–76.1) 1 (ref)b
5-9 83.9 (82.3–85.3) 71.5 (69.6–73.3) 1.14 (1.03–1.27)
10-14 90.9 (89.6–92.1) 79.4 (77.5–81.2) 0.78 (0.69-0.88)
15-19 92.7 (91.3–93.8) 77.7 (71.6–76.4) 0.82 (0.73-0.94)
Sex Male 86.8 (85.8–87.7) 73.7 (72.4–75.0) 1 (ref) 0.09
Female 86.9 (85.8–87.9) 75.5 (74.1–76.8) 0.93 (0.86–1.01)
Year of diagnosis 2000-2003 85.7 (84.2–87.0) 73.6 (71.8–75.3) 1 (ref) 0.4
2004-2007 86.8 (85.4–88.2) 74.7 (72.9–76.5) 0.95 (0.85–1.05)
2008-2011 86.8 (85.3–88.0) 75.5 (73.7–77.2) 0.92 (0.82–1.02)
2012-2015 88.2 (86.7–89.6) – 0.95 (0.84–1.08)
Tumour typec Astrocytoma (low grade) 98.2 (97.6–98.6) 95.5 (94.7–96.3) 1 (ref)b < 0.0001
Astrocytoma (high grade) 61.2 (57.5–64.8) 23.4 (20.0–26.9) 26.16 (21.68–31.57)
Astrocytoma (other) 93.1 (91.0–94.8) 83.9 (80.8–86.6) 3.51 (2.74–4.49)
Ependymoma 94.9 (93.1–96.3) 76.7 (73.1–79.9) 5.46 (4.38–6.81)
Medulloblastoma/PNET 86.3 (84.6–87.9) 68.9 (66.4–71.2) 7.84 (6.50–9.44)
Other 78.1 (76.4–79.6) 65.9 (63.9–67.7) 8.54 (7.15–10.21)
Type of health insurance (restricted to 2007 onwards) Insured (private) 88.5 (87.3–89.7) 76.1 (74.2–77.8) 1 (ref)b < 0.0001
Insured (Medicaid) 85.6 (83.7–87.2) 70.3 (67.7–72.8) 1.32 (1.17–1.50)
Insured (Unknown type) 88.5 (85.5–91.0) 80.9 (77.0–84.2) 0.82 (0.66–1.02)
No insurance 86.1 (76.8–91.9) 76.0 (64.7–84.1) 1.03 (0.65–1.63)
Unknown 82.6 (74.7–88.2) 75.1 (65.9–82.1) 1.28 (0.89–1.83)
Staged Localised 89.2 (88.4–89.9) 78.0 (77.0–79.0) 1 (ref) < 0.0001
Regional 78.2 (75.6–80.6) 60.8 (57.6–63.9) 1.97 (1.76–2.19)
Distant 74.9 (71.0–78.4) 56.4 (51.8–60.7) 2.48 (2.16–2.84)
a Likelihood ratio (LR) test p-value.
b Reference as largest group.
c Astrocytoma high-grade (International Classification of Disease for Oncology 3rd Edition morphology codes 9401, 9411, 9440, 9441), astrocytoma low-grade
(9421, 9424, 9410, 9420), astrocytoma other (9400, 9422, 9423, 9430), ependymoma (9391, 9392, 9393, 9394), and medulloblastoma/Primitive Neuro Ectodermal
Tumours (PNET) (9470, 9471, 9472, 9364, 9473). All remaining tumours were classified as ‘other’.
d Excluding 624 children with unknown stage at diagnosis.
Fig. 3. Kaplan-Meier graph of overall survival of children and adolescents (0–19) diagnosed with a first primary CNS tumour between 2000 and 2015, by race/
ethnicity.
(Note: y-axis restricted from 0.5 to 1).
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Analyses considering an interaction between race/ethnicity and time
since diagnosis (up to or after 2.5 years) showed a slightly smaller as-
sociation between race/ethnicity and survival for Hispanics after 2.5
years after diagnosis (not shown).
4. Discussion
This study used the most recent population-based data available to
assess the influence of race/ethnicity and SEP on survival in children
and adolescents diagnosed with a CNS tumour in the US. There was a
clear relationship between race/ethnicity and SEP, with a higher pro-
portion of Black and Hispanic children residing in the most deprived
versus least deprived areas. A substantially higher proportion of White
children had private insurance compared to Hispanic and Black chil-
dren.
We found striking evidence of survival inequalities by racial/ethnic
group. Black and Hispanic children had increased hazard of death
compared to White children, and this association did not appear to be
fully explained by differences in SEP, stage at diagnosis or tumour type,
as the effect of race/ethnicity was only slightly attenuated when ad-
justed for these variables. Conversely, the apparent effect of SEP on
survival was markedly attenuated after adjustment for race/ethnicity
and insurance status. This suggests that the apparent influence of SEP
on survival was largely explained by race/ethnicity and individual-level
insurance status. Insurance status was not itself associated with sur-
vival.
These findings are based on a large population-based cohort, with
high-quality data of the SEER Programme on children diagnosed with
CNS tumour over a 15-year period. There is high ascertainment of all
incident tumours in the areas covered by SEER, with linkage to death
database and low loss to follow-up (approximately 7 % at five years of
diagnosis). Detailed demographic and clinical information was avail-
able [26]. The measure used to quantify SEP was the Yost Index, which
is based on census tract-level socioeconomic indices. As an ecological-
level variable, this has some limitations, mainly the assumption of
homogeneity of people living in the same census tract. Although the
census tract-level geographic areas are small, this potential non-dif-
ferential misclassification means the true effects of SEP on survival
might be under-estimated here. However, although some aspects of an
individual’s SEP might not be completely captured by census level SEP,
some research has suggested that both individual and geographic-level
measures of SEP have similar association with outcome [27]. In-
dividual-level insurance status data were available for 2007 onwards
and this could also serve as a proxy for individual SEP, but this measure
does not allow for the capture of differing degrees of socioeconomic
disparity.
We analysed the three largest categories of race/ethnicity in the US,
but children of mixed race/ethnicity and other minority groups were
not included due to small numbers. Potential misclassification of race/
ethnicity obtained by SEER may have influenced the association be-
tween race/ethnicity and survival. However, previous studies using US
cancer registry data, showed that this variable is of high-quality for self-
Fig. 4. Kaplan-Meier graph of overall survival of children and adolescents (0–19) diagnosed with a first primary CNS tumour between 2000 and 2015, by SEP.
(Note: y-axis restricted from 0.5 to 1)
Table 3
Adjusted hazard ratios by race/ethnicity and SEP for overall survival of children and adolescents diagnosed with a first primary CNS tumour in SEER data 2000–2015
(n=9577 in all models).
Partially adjusteda Fully adjustedb
aHR (95 % CI) p-valuec aHR (95 % CI) p-valuec
Race/ethnicity Non-Hispanic White 1 (ref) < 0.0001 1 (ref) < 0.0001
Non Hispanic Black 1.46 (1.29–1.65) 1.39 (1.23–1.58)
Hispanic 1.48 (1.35–1.61) 1.40 (1.28–1.54)
SEP (Yost) quintile 5 - least deprived 1 (ref) < 0.0001 1 (ref) < 0.0001
4 1.17 (1.02–1.33) 1.13 (0.99–1.29)
3 1.29 (1.12–1.47) 1.20 (1.05–1.37)
2 1.35 (1.18–1.54) 1.21 (1.06–1.39)
1 - most deprived 1.46 (1.29–1.66) 1.23 (1.08–1.41)
Final sample includes 624 patients with information missing on stage as this variable was not used in final model.
a Adjusted for sex, age, year of diagnosis and tumour category only.
b Adjusted for sex, age, year of diagnosis and tumour category and other variables in the table (race/ethnicity and SEP).
c Likelihood ratio (LR) test p-value.
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reported race/ethnicity for White and Black patients and of moderate
quality for Hispanic patients [28].
Information on the type of treatment received was not available for
the majority of children, and was therefore not analysed. Information
on stage at diagnosis was missing for a substantial part of the eligible
cohort, and therefore restricted to sensitivity analyses. Future research
using these data would be important in elucidating the mechanisms
behind survival disparities, as one can hypothesise that being diagnosed
at a later stage, or receiving suboptimal treatment, could explain some
of the survival inequalities.
Our results confirm the persistence of racial/ethnic disparities in
survival of childhood CNS tumour observed up to year 2011 [8,11–13],
using a more recent and larger data set. In the US, socioeconomic dis-
parity is often associated with race/ethnicity, warranting the need to
consider the two factors together [29]. In 2016, 22 % of the Black
population and 19 % of the Hispanic population lived below the pov-
erty line, while the figure was 9 % for the White population [30]. Our
study suggests that the association between race/ethnicity and CNS
tumour survival in children is, if at all, little confounded by SEP and
insurance status. A recent analysis of SEER data covering years
2000–2011 also reported racial/ethnic disparities in survival for several
types of childhood cancer, including astrocytomas and non-astrocytoma
CNS tumours [13]. In this study, there was no evidence that the asso-
ciation between race/ethnicity and survival for non-astrocytoma CNS
tumours was mediated by SEP. The authors discussed the possibility
that the effect of race/ethnicity on survival from CNS tumours could be
mediated by other factors not encapsulated within area-based SEP, such
as differences in tumour biology and other social factors [13]. Our re-
sults support the low confounding effect of SEP on the association be-
tween race/ethnicity and CNS tumour survival. In addition, this parti-
cularly robust association remained stable despite accounting for the
differences in distribution of prognostic-based tumour type and stage by
race/ethnicity. Whilst, we cannot rule out that other biological and/or
genetics differences explain this association, there is evidence from
clinical trials at a large US children’s cancer hospital showing that, with
access to equal treatment for the same type of tumour, Black children
with cancer had equivalent survival to White children [31]. Whilst
evidence coming from clinical trial data must be interpreted with
caution due to racial differences in enrollment [32], these results
showing that equal treatment may reduce or eliminate the racial sur-
vival disparities among children with cancer, together with our find-
ings, support the hypothesis that the observed racial/ethnic survival
disparities could be due to differential access to optimal healthcare.
Individual insurance data has only been collected by SEER since
2007, therefore research investigating its impact is still limited. A US
study from 2007 to 2009 found an increased risk of cancer death in
uninsured children, however numbers were small [33]. Importantly in
our study, comparable survival was seen between children who were
privately insured and those who were insured under a Medicaid pro-
gramme, suggesting that access to insurance, either public or private,
might reduce survival inequalities. Results on absence of insurance
must still be interpreted with caution, as numbers are small for unin-
sured children. In addition, misclassification of insurance data has been
reported in children who initially presented for healthcare without in-
surance (therefore, registered as uninsured), but who later obtained
insurance, as in many US states, uninsured patients may get Medicaid
coverage after a cancer diagnosis [33]. Therefore, the true effect of
being uninsured or underinsured on the risk of death could have been
underestimated in our study.
It is possible that some personal reasons could lead those without
insurance or of lower SEP to present to healthcare at a more advanced
stage of disease, such as fear of medical costs or fear of legal re-
percussions among those with uncertain migrant status. In addition,
children in lower SEP areas could have access to suboptimal healthcare
leading to poorer outcomes. We cannot rule out that the increased
hazard of death observed in Black and Hispanic children after adjust-
ment for area-level SEP could be partly explained by residual con-
founding by individual SEP. However, independently of SEP, the as-
sociation with race/ethnicity could be related to racially/ethnically
driven barriers to accessing adequate healthcare. Whilst it is difficult to
unravel the mechanisms leading to this, implicit bias against minority
groups in healthcare providers is well documented [34]. The presenting
symptoms of CNS tumour can often be vague and non-specific, for ex-
ample dizziness, vomiting, headache, altered gait, or changes in per-
sonality. Black or Hispanic children and those of lower SEP might be
less likely to have such symptoms further investigated by healthcare
workers. These barriers to seeking and receiving care for such symp-
toms may therefore delay diagnosis. Future analyses taking account of
the pathway of care, not available in these data, might help better
understand the mechanisms underlying these disparities.
5. Conclusions
This study shows strong survival disparities by race/ethnicity in
Table 4
Adjusted hazard ratios by race/ethnicity, SEP and individual insurance status for overall survival of children and adolescents diagnosed with a first primary CNS
tumour in SEER data, 2007–2015 (n=5429 in both models).
Partially adjusteda Fully adjustedb
aHR (95 % CI) p-value aHR p-valuec
Race/ethnicity Non-Hispanic White 1 (ref) < 0.0001 1 (ref) 0.0001
Non-Hispanic Black 1.34 (1.11–1.60) 1.25 (1.04–1.51)
Hispanic 1.42 (1.25–1.61) 1.34 (1.17–1.54)
SEP (Yost) quintile 5 least deprived 1 (ref) 0.0007 1 (ref) 0.2
4 1.10 (0.91–1.33) 1.07 (0.88–1.30)
3 1.25 (1.03–1.51) 1.17 (0.96–1.42)
2 1.31 (1.08–1.58) 1.20 (0.98–1.46)
1 most deprived 1.45 (1.20–1.74) 1.26 (1.03–1.55)
Type of health insurance (2007 onwards) Insured (Private) 1 (ref) 0.007 1 (ref) 0.2
Insured (Medicaid) 1.18 (1.04–1.34) 1.01 (0.87–1.16)
Insured (unknown type) 0.83 (0.67–1.03) 0.82 (0.66–1.02)
No insurance 1.07 (0.68–1.69) 0.97 (0.61–1.53)
Unknown 1.40 (0.97–2.01) 1.36 (0.94–1.96)
Final sample includes 624 patients with information missing on stage as this variable was not used in final model.
There was no evidence of interaction between race/ethnicity and SEP (pint= 0.2).
a Adjusted for sex, age, year of diagnosis and tumour category only.
b Adjusted for sex, age, year of diagnosis and tumour category and other variables in the table (race/ethnicity, SEP and insurance).
c Likelihood ratio (LR) test p-value.
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children and adolescents diagnosed with CNS tumour in the US be-
tween 2000 and 2015. The findings parallel the large and growing body
of evidence on outcome disparities by race/ethnicity in childhood and
adolescent cancer in the US. Further work with reliable and complete
information on tumour type, stage at diagnosis and treatment will be
crucial to understanding the mechanisms by which these disparities
occur. Further research into the healthcare access barriers faced by
minority groups would also be crucial and together these could be the
basis for healthcare policies aimed at eliminating these unacceptable
survival inequalities.
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